Intensification lessons with modern premixes: From clinical trial to clinical practice

被引:11
作者
Guler, Serdar [3 ]
Vaz, Julius A. [2 ]
Lithelm, Robert [1 ]
机构
[1] EHM Clin Hoofddorp, NL-3062 ZB Rotterdam, Netherlands
[2] Novo Nordisk Int Operat Clin Ctr, Singapore, Singapore
[3] Ankara Numune Training & Res Hosp, Ankara, Turkey
关键词
initiation; intensification; biphasic insulin aspart 30; type; 2; diabetes;
D O I
10.1016/j.diabres.2008.06.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This paper aims to underscore the importance of insulin intensification, while highlighting the clinical utility of modem premixes through intensification lessons, by utilising data from key clinical trials, and from the recently published large observational PRESENT Study. insulin intensification is any change made to an initial insulin regimen to improve glycaemic control. Yet, despite established glycaemic targets, current HbA1c levels in insulin-treated patients suggest that 'real-world' insulin regimens are not optimally intensified. When treatment is intensified as needed, patients are more likely to achieve and maintain glycaemic targets, as evidenced by treat-to-target trials utilising forced titration algorithms. Both clinical and observational studies suggest that modem premixes, such as biphasic insulin aspart 30, represent an effective and well-tolerated option when intensifying a number of existing insulin regimens that no longer maintain optimal glycaemic control. However, physician and patient concerns regarding initiation and intensification of insulin therapy can create barriers to effective patient care, and it is essential that such barriers be resolved. Although it is important to encourage patients to initiate insulin therapy when needed, it is equally important that insulin regimens benefit from ongoing intensification in order to maintain glycaemic control as type 2 diabetes follows its typically progressive course. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:S23 / S30
页数:8
相关论文
共 31 条
[1]  
*AACE DIAB MELL CL, 2007, ENDOCR PRACT S1, V13, P1
[2]  
[Anonymous], 2007, DIABETES CARE, DOI DOI 10.2337/DC07-S004
[3]   Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients [J].
Boehm, BO ;
Home, PD ;
Behrendt, C ;
Kampt, NM ;
Lindholm, A .
DIABETIC MEDICINE, 2002, 19 (05) :393-399
[4]   Treating the whole patient for optimal management of type 2 diabetes: Considerations for insulin therapy [J].
Campos, Carlos .
SOUTHERN MEDICAL JOURNAL, 2007, 100 (08) :804-811
[5]   Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes [J].
Christiansen, JS ;
Vaz, JA ;
Metelko, Z ;
Bogoev, M ;
Dedov, I .
DIABETES OBESITY & METABOLISM, 2003, 5 (06) :446-454
[6]  
Dailey G, 2005, FORMULARY, V40, P114
[7]   Improvement of glycemic control in subjects with poorly controlled type 2 diabetes - Comparison of two treatment algorithms using insulin glargine [J].
Davies, M ;
Storms, F ;
Shutler, S ;
Bianchi-Biscay, M ;
Gomis, R .
DIABETES CARE, 2005, 28 (06) :1282-1288
[8]  
De Leiva A, 2006, DIABETES, V55, pA109
[9]   Far from goal [J].
Del Prato, S .
DIABETES OBESITY & METABOLISM, 2005, 7 :S1-S4
[10]   Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study) [J].
Garber, AJ ;
Wahlen, J ;
Wahl, T ;
Bressler, P ;
Braceras, R ;
Allen, E ;
Jain, R .
DIABETES OBESITY & METABOLISM, 2006, 8 (01) :58-66